Table 3 of Benitez-del-Castillo, Mol Vis 2021; 27:243-261.

Table 3. Demographic and clinical data of the patients included in the study.

Demographic data Group
Control Mild Moderate Severe
Age 54.57 ± 10.31 57.26 ± 6.02 59.10 ± 12.97 56.85 ± 8.53
Sex % (F/M) 64.28/35.72 75/25 73.68/26.32 100/0
MH (mm) 0.33 ± 0.1 0.32 ± 0.08 0.32 ± 0.15 0.25 ± 0.07
TBUT 10.54 ± 0.88 5.72 ± 1.56* 4.14 ± 1.64* 2.75 ± 1.65*
MGQ 0.71 ± 2.19 8.25 ± 2.31* 8.97 ± 3.96* 11 ± 4.23*
MGE 0.07 ± 0.26 0.41 ± 0.56* 1.16 ± 0.82* 1.35 ± 0.59*
MGD STAGE 0.18 ± 0.48 1.59 ± 0.8* 2.34 ± 1.05* 2.55 ± 0.89*
FLUO 0 0.94 ± 0.25* 0.95 ± 0.32* 1*
LG 0 0.03 ± 0.18 0.18 ± 0.39 0
SCH 16.29 ± 5.76 8.63 ± 1.68* 8.18 ± 2.54* 4.20 ± 2.80*
OSM 304.04 ± 8.83 301.72 ± 10.12 301.11 ± 17.92 301.20 ± 16.44
OSDI 6.31 ± 4.03 16.06 ± 17.19* 30.50 ± 19.01* 35.92 ± 26.18*

MH, meniscus height; TBUT, tear breakup time; MGQ, meibomian gland quality; MGE, meibomian gland expression; MGD, meibomian gland dysfunction; FLUO, fluorescein; LG, lissamine green; SCH, Schirmer test; OSM, osmolarity; OSDI, Ocular Surface Disease Index. Asterisks indicate significant differences in comparison with controls. p-value < 0.001.

Benitez-del-Castillo, Mol Vis 2021; 27:243-261. http://www.molvis.org/molvis/v27/243

©2021 Molecular Vision http://www.molvis.org/molvis/

ISSN 1090-0535